Double-Blind Trial of Miglitol in Type 2 Diabetic Patients Treated With Biguanide

This study has been completed.

First Received: May 26, 2006 Last Updated: October 8, 2008 History of Changes

Sponsored by:	Sanwa Kagaku Kenkyusho Co., Ltd.
Information provided by:	Sanwa Kagaku Kenkyusho Co., Ltd.
ClinicalTrials.gov Identifier:	NCT00334399

Purpose

The purpose of this study is to evaluate the clinical efficacy and safety of Miglitol in patients with Type2 Diabetes Mellitus treated with Biguanide.

Condition	Intervention	Phase
Type 2 Diabetes Mellitus	Drug: Miglitol	Phase III

MedlinePlus related topics: Diabetes

Drug Information available for: Miglitol

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Eligibility

Ages Eligible for Study:	20 Years to 69 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Type 2 diabetic patients treated with Biguanide
Criteria for postprandial plasma glucose and HbA1c are met

Exclusion Criteria:

Type 1 diabetes
Patients treated with other antidiabetic drugs or Insulin

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00334399

Locations

Japan

Hokkaido, Japan

Ibaragi, Japan

Gunma, Japan

Saitama, Japan

Chiba, Japan

Kanagawa, Japan

Tochigi, Japan

Aichi, Japan

Osaka, Japan

Fukuoka, Japan

Kumamoto, Japan

Miyazaki, Japan

Gifu, Japan

Sponsors and Collaborators

Sanwa Kagaku Kenkyusho Co., Ltd.

Investigators

Study Director:

Clinical Study Group, Clinical Development Dept.

Sanwa Kagaku Kenkyusho Co., Ltd.

More Information

No publications provided

Study ID Numbers:	MG1008
Study First Received:	May 26, 2006
Last Updated:	October 8, 2008
ClinicalTrials.gov Identifier:	NCT00334399 History of Changes
Health Authority:	Japan: Ministry of Health, Labor and Welfare

Keywords provided by Sanwa Kagaku Kenkyusho Co., Ltd.:

alpa-glucosidase inhibitor,Biguanide

Study placed in the following topic categories:

Miglitol
Hypoglycemic Agents
Metabolic Diseases
Diabetes Mellitus, Type 2
Diabetes Mellitus

Endocrine System Diseases
Endocrinopathy
Glucose Metabolism Disorders
Metabolic Disorder

Additional relevant MeSH terms:

Miglitol
Hypoglycemic Agents
Metabolic Diseases
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Diabetes Mellitus, Type 2

Diabetes Mellitus
Endocrine System Diseases
Enzyme Inhibitors
Glucose Metabolism Disorders
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 06, 2009